Mouse models for infectious diseases caused by Staphylococcus aureus

Journal of Immunological Methods

Volumn 410, Issue , 2014, Pages 88-99

  Kim, Hwan Keun ^a   Missiakas, Dominique ^a   Schneewind, Olaf ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Animal model; Mouse; Staphylococcus aureus

Indexed keywords

STAPHYLOCOCCUS VACCINE; VIRULENCE FACTOR;

ABSCESS; ADAPTIVE IMMUNITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; BONE REMODELING; EXPERIMENTAL INFECTION; IMMUNOTHERAPY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE MODEL; NONHUMAN; PATHOLOGIC FRACTURE; PERSISTENT INFECTION; SEPSIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; VACCINE FAILURE; VEIN THROMBOSIS; ANIMAL; ANIMAL MODEL; DISEASE MODEL; HUMAN; IMMUNE EVASION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOUSE; PATHOLOGY; REVIEW;

ANIMAL MODEL; MOUSE; STAPHYLOCOCCUS AUREUS;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES;

EID: 84908499334     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.04.007     Document Type: Article

References (182)

1. Agarwal D.S. Subcutaneous staphylococcal infection in mice. I. The role of cotton-dust in enhancing infection. Br. J. Exp. Pathol. 1967, 48:436.
2. Albus A., Arbeit R.D., Lee J.C. Virulence studies of Staphylococcus aureus mutants altered in type 5 capsule production. Infect. Immun. 1991, 59:1008.
3. Alonzo F.r., Benson M.A., Chen J., Novick R.P., Shopsin B., Torres V.J. Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol. Microbiol. 2012, 83:423.
4. Alonzo F.r., Kozhaya L., Rawlings S.A., Reyes-Robles T., DuMont A.L., Myszka D.G., Landau N.R., Unutmaz D., Torres V.J. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013, 493:51.
5. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 2004, 38:1673.
6. Arrecubieta C., Asai T., Bayern M., Loughman A., Fitzgerald J.R., Shelton C.E., Baron H.M., Dang N.C., Deng M.C., Naka Y., Foster T.J., Lowy F.D. The role of Staphylococcus aureus adhesins in the pathogenesis of ventricular assist device-related infections. J. Infect. Dis. 2006, 193:1109.
7. Arrecubieta C., Matsunaga I., Asai T., Naka Y., Deng M.C., Lowy F.D. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J. Infect. Dis. 2008, 198:571.
8. Asai A., Tsuda Y., Kobayashi M., Hanafusa T., Herndon D.N., Suzuki F. Pathogenic role of macrophages in intradermal infection of methicillin-resistant Staphylococcus aureus in thermally injured mice. Infect. Immun. 2010, 78:4311.
9. Baba T., Bae T., Schneewind O., Takeuchi F., Hiramatsu K. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes. J. Bacteriol. 2007, 190:300.
10. Bagnoli F., Bertholet S., Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front. Cell. Infect. Microbiol. 2012, 2:16.
11. Becherelli M., Prachi P., Viciani E., Biagini M., Fiaschi L., Chiarot E., Nosari S., Brettoni C., Marchi S., Biancucci M., Fontana M.R., Montagnani F., Bagnoli F., Barocchi M.A., Manetti A.G. Protective activity of the CnaBE3 domain conserved among Staphylococcus aureus Sdr proteins. PLoS One 2013, 8:e74718.
12. Behring E.A. Über das Zustandekommen der Diphtherie-Immunität bei Thieren. Dtsch. Med. Wochenschr. 1890, 16:1145.
13. Belthur M.V., Birchansky S.B., Verdugo A.A., Mason E.O., Hulten K.G., Kaplan S.L., Smith E.O., Phillips W.A., Weinberg J. Pathologic fractures in children with acute Staphylococcus aureus osteomyelitis. J. Bone Joint Surg. Am. 2012, 94:34.
14. Berends E.T., Horswill A.R., Haste N.M., Monestier M., Nizet V., von Köckritz-Blickwede M. Nuclease expression by Staphylococcus aureus facilitates escape from neutrophil extracellular traps. J. Innate Immun. 2010, 2:576.
15. Bernthal N.M., Stavrakis A.I., Billi F., Cho J.S., Kremen T.J., Simon S.I., Cheung A.L., Finerman G.A., Lieberman J.R., Adams J.S., Miller L.S. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One 2010, 5:e12580.
16. Bieber T. Atopic dermatitis. N. Engl. J. Med. 2008, 358:1483.
17. Bor D.H., Woolhandler S., Nardin R., Brusch J., Himmelstein D.U. Infective endocarditis in the U.S., 1998-2009: a nationwide study. PLoS One 2013, 8:e60033.
18. Bremell T., Lange S., Yacoub A., Ryden C., Tarkowski A. Experimental Staphylococcus aureus arthritis in mice. Infect. Immun. 1991, 59:2615.
19. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 2008, 205:287.
20. Bubeck Wardenburg J., Patel R.J., Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect. Immun. 2007, 75:1040.
21. Bubeck Wardenburg J., Missiakas D.M., Schneewind O. Vaccines for Staphylococcus aureus Infections. New Generation Vaccines 2008, Informa Health Care, Washington, D.C. M.M. Levine, J.B. Kaper, R. Rappuoli, M.F. Liu, A.L. Good (Eds.).
22. Bukowski M., Wladyka B., Dubin G. Exfoliative toxins of Staphylococcus aureus. Toxins (Basel) 2010, 2:1148.
23. Bunce C., Wheeler L., Reed G., Musser J., Barg N. Murine model of cutaneous infection with gram-positive cocci. Infect. Immun. 1992, 60:2636.
24. Calander A.M., Jonsson I.M., Kanth A., Arvidsson S., Shaw L., Foster S.J., Tarkowski A. Impact of staphylococcal protease expression on the outcome of infectious arthritis. Microbes Infect. 2004, 6:202.
25. Cassat J.E., Hammer N.D., Campbell J.P., Benson M.A., Perrien D.S., Mrak L.N., Smeltzer M.S., Torres V.J., Skaar E.P. A secreted bacterial protease tailors the Staphylococcus aureus virulence repertoire to modulate bone remodeling during osteomyelitis. Cell Host Microbe 2013, 13:759.
26. Chambers H.F. Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. 2005, 352:1485.
27. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., Pupp G.R., Brown W.J., Cardo D., Fridkin S.K., Team, V.-R.S.a.I Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 2003, 348:1342.
28. Chatterjee S.S., Joo H.S., Duong A.C., Dieringer T.D., Tan V.Y., Song Y., Fischer E.R., Cheung G.Y., Li M., Otto M. Essential Staphylococcus aureus toxin export system. Nat. Med. 2013, 19:364.
29. Cheng A.G., Kim H.K., Burts M.L., Krausz T., Schneewind O., Missiakas D.M. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 2009, 23:3393.
30. Cheng A.G., McAdow M., Kim H.K., Bae T., Missiakas D.M., Schneewind O. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 2010, 6.
31. Cheng A.G., McAdow M., Kim H.K., Bae T., Missiakas D.M., Schneewind O. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 2010, 6:e1001036.
32. Cheng A.G., DeDent A.C., Schneewind O., Missiakas D. A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol. 2011, 19:225.
33. Cheung G.Y., Kretschmer D., Queck S.Y., Joo H.S., Wang R., Duong A.C., Nguyen T.H., Bach T.H., Porter A.R., Deleo F.R., Peschel A., Otto M. Insight into structure-function relationship in phenol-soluble modulins using an alanine screen of the phenol-soluble modulin (PSM) alpha3 peptide. FASEB J. 2014, 28:153.
34. Cho J.S., Pietras E.M., Garcia N.C., Ramos R.I., Farzam D.M., Monroe H.R., Magorien J.E., Blauvelt A., Kolls J.K., Cheung A.L., Cheng G., Modlin R.L., Miller L.S. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 2010, 120:1762.
35. Crowley A.L., Peterson G.E., Benjamin D.K., Rimmer S.H., Todd C., Cabell C.H., Reller L.B., Ryan T., Corey G.R., Fowler V.G. Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit. Care Med. 2008, 36:385.
36. Dedent A., Kim H.K., Missiakas D., Schneewind O. Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin. Immunopathol. 2012, 34:317.
37. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981, 20:2361.
38. Deivanayagam C.C., Rich R.L., Carson M., Owens R.T., Danthuluri S., Bice T., Höök M., Narayana S.V. Novel fold and assembly of the repetitive B region of the Staphylococcus aureus collagen-binding surface protein. Structure 2000, 8:67.
39. DeLeo F.R., Chambers H.F. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 2009, 7:629.
40. Diep B.A., Gill S.R., Chang R.F., Phan T.H., Chen J.H., Davidson M.G., Lin F., Lin J., Carleton H.A., Mongodin E.F., Sensabaugh G.F., Perdreau-Remington F. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006, 367:731.
41. DuMont A.L., Yoong P., Surewaard B.G., Benson M.A., Nijland R., van Strijp J.A., Torres V.J. Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophils. Infect. Immun. 2013, 81:1830.
42. DuMont A.L., Yoong P., Day C.J., Alonzo F.r., McDonald W.H., Jennings M.P., Torres V.J. Staphylococcus aureus LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10794.
43. Falugi F., Kim H.K., Missiakas D.M., Schneewind O. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. mBio 2013, 4:e00575.
44. Fattom A.I., Sarwar J., Ortiz A., Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 1996, 64:1659.
45. Fattom A.I., Horwith G., Fuller S., Propst M., Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004, 22:880.
46. Federspiel J.J., Stearns S.C., Peppercorn A.F., Chu V.H., Fowler V.G. Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008. Arch. Intern. Med. 2012, 172:363.
47. Fitzgerald J.R. Human origin for livestock-associated methicillin-resistant Staphylococcus aureus. mBio 2012, 3:e00082.
48. Fitzgerald J.R. Livestock-associated Staphylococcus aureus: origin, evolution and public health threat. Trends Microbiol. 2012, 20:192.
49. Flick M.J., Du X., Prasad J.M., Raghu H., Palumbo J.S., Smeds E., Höök M., Degen J.L. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood 2013, 121:1783.
50. Fluit A.C. Livestock-associated Staphylococcus aureus. Clin. Microbiol. Infect. 2012, 18:735.
51. Forsgren A., Quie P.G. Effects of staphylococcal protein A on heat labile opsonins. J. Immunol. 1974, 112:1177.
52. Forsgren A., Sjöquist J. Protein A from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J. Immunol. 1966, 97:822.
53. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3:948.
54. Fowler V.G., Miro J.M., Hoen B., Cabell C.H., Abrutyn E., Rubinstein E., Corey G.R., Spelman D., Bradley S.F., Barsic B., Pappas P.A., Anstrom K.J., Wray D., Fortes C.Q., Anguera I., Athan E., Jones P., van der Meer J.T., Elliott T.S., Levine D.P., Bayer A.S. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005, 293:3012.
55. Fowler V.G., Allen K.B., Moreira E.D., Moustafa M., Isgro F., Boucher H.W., Corey G.R., Carmeli Y., Betts R., Hartzel J.S., Chan I.S., McNeely T.B., Kartsonis N.A., Guris D., Onorato M.T., Smugar S.S., DiNubile M.J., Sobanjo-ter Meulen A. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013, 309:1368.
56. Frank K.M., Zhou T., Moreno-Vinasco L., Hollett B., Garcia J.G., Bubeck Wardenburg J. Host response signature to Staphylococcus aureus alpha-hemolysin implicates pulmonary Th17 response. Infect. Immun. 2012, 80:3161.
57. Fridkin S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 2001, 32:108.
58. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., Harriman K., Harrison L.H., Lynfield R., Farley M.M. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 2005, 352:1436.
59. Friedrich R., Panizzi P., Fuentes-Prior P., Richter K., Verhamme I., Anderson P.J., Kawabata S., Huber R., Bode W., Bock P.E. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 2003, 425:535.
60. Ganesh V.K., Rivera J.J., Smeds E., Ko Y.-P., Bowden M.G., Wann E.R., Gurusidappa S., Fitzgerald J.R., Höök M. A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog. 2008, 4:e1000226.
61. Gerber J.S., Coffin S.E., Smathers S.A., Zaoutis T.E. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin. Infect. Dis. 2009, 49:65.
62. Gibson G.W., Kreuser S.C., Riley J.M., Rosebury-Smith W.S., Courtney C.L., Juneau P.L., Hollembaek J.M., Zhu T., Huband M.D., Brammer D.W., Brieland J.K., Sulavik M.C. Development of a mouse model of induced Staphylococcus aureus infective endocarditis. Comp. Med. 2007, 57:563.
63. Gillet Y., Issartel B., Vanhems P., Lina G., Vandenesch F., Etienne J., Floret D. Severe staphylococcal pneumonia in children. Arch. Pediatr. 2001, 8(Suppl. 4):742s.
64. Gomez M.I., Lee A., Reddy B., Muir A., Soong G., Pitt A., Cheung A., Prince A. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat. Med. 2004, 10:842.
65. Gomez M.I., Lee A., Reddy B., Muir A., Soong G., Pitt A., Cheung A., Prince A. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat. Med. 2004, 10:842.
66. Gomez M.I., O'Seaghdha M., Magargee M., Foster T.J., Prince A.S. Staphylococcus aureus protein A activates TNFR1 signaling through conserved IgG binding domains. J. Biol. Chem. 2006, 281:20190.
67. Gómez M.I., O'Seaghdha M., Prince A.S. Staphylococcus aureus protein A activates TACE through EGFR-dependent signaling. EMBO J. 2007, 26:701.
68. Goodyear C.S., Silverman G.J. Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin. J. Exp. Med. 2003, 197:1125.
69. Gordon R.J., Quagliarello B., Lowy F.D. Ventricular assist device-related infections. Lancet Infect. Dis. 2006, 6:426.
70. Gorwitz R.J., Kruszon-Moran D., McAllister S.K., McQuillan G., McDougal L.K., Fosheim G.E., Jensen B.J., Killgore G., Tenover F.C., Kuehnert M.J. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J. Infect. Dis. 2008, 197:1226.
71. Graille M., Stura E.A., Corper A.L., Sutton B.J., Taussig M.J., Charbonnier J.B., Silverman G.J. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5399.
72. Gresham H.D., Lowrance J.H., Caver T.E., Wilson B.S., Cheung A.L., Lindberg F.P. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 2000, 164:3713.
73. Gupta R.K., Alba J., Xiong Y.Q., Bayer A.S., Lee C.Y. MgrA activates expression of capsule genes, but not the α-toxin gene in experimental Staphylococcus aureus endocarditis. J. Infect. Dis. 2013, 208:1841.
74. Hahn B.L., Onunkwo C.C., Watts C.J., Sohnle P.G. Systemic dissemination and cutaneous damage in a mouse model of staphylococcal skin infections. Microb. Pathog. 2009, 47:16.
75. Harris S.R., Feil E.J., Holden M.T., Quail M.A., Nickerson E.K., Chantratita N., Gardete S., Tavares A., Day N., Lindsay J.A., Edgeworth J.D., de Lencastre H., Parkhill J., Peacock S.J., Bentley S.D. Evolution of MRSA during hospital transmission and intercontinental spread. Science 2010, 327:469.
76. Heyworth P.G., Cross A.R., Curnutte J.T. Chronic granulomatous disease. Curr. Opin. Immunol. 2003, 15:578.
77. Holtfreter S., Radcliff F.J., Grumann D., Read H., Johnson S., Monecke S., Ritchie S., Clow F., Goerke C., Bröker B.M., Fraser J.D., Wiles S. Characterization of a mouse-adapted Staphylococcus aureus strain. PLoS One 2013, 8:e71142.
78. Hurd A.F., Garcia-Lara J., Rauter Y., Cartron M., Mohamed R., Foster S.J. The iron-regulated surface proteins IsdA, IsdB, and IsdH are not required for heme iron utilization in Staphylococcus aureus. FEMS Microbiol. Lett. 2012, 329:93.
79. Inoshima I., Inoshima N., Wilke G.A., Powers M.E., Frank K.M., Wang Y., Bubeck Wardenburg J. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat. Med. 2011, 17:1310.
80. Iwakura Y., Nakae S., Saijo S., Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol. Rev. 2008, 226:57.
81. Jonsson I.M., Mazamanian S.K., Schneewind O., Vendrengh M., Bremell T., Tarkowski A. On the role of Staphylococcus aureus sortase and sortase-catalyzed surface protein anchoring in murine septic arthritis. J. Infect. Dis. 2002, 185:1417.
82. Josefsson E., Hartford O., O'Brien L., Patti J.M., Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 2001, 184:1572.
83. Josefsson E., Higgins J., Foster T.J., Tarkowski A. Fibrinogen binding sites P336 and Y338 of clumping factor are crucial for Staphylococcus aureus virulence. PLoS One 2008, 3:e2206.
84. Kallen A.J., Mu Y., Bulens S., Reingold A., Petit S., Gershman K., Ray S.M., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Schaffner W., Patel P., Fridkin S.K., Program., A.B.C.s.A.M.I.o.t.E.I. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010, 304:641.
85. Kennedy A.D., Bubeck Wardenburg J., Gardner D.J., Long D., Whitney A.R., Braughton K.R., Schneewind O., DeLeo F.R. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 2010, 202:1050.
86. Kernodle D.S., Voladri R.K., Menzies B.E., Hager C.C., Edwards K.M. Expression of an antisense hla fragment in Staphylococcus aureus reduces alpha-toxin production in vitro and attenuates lethal activity in a murine model. Infect. Immun. 1997, 65:179.
87. Kim H.K., DeDent A., Cheng A.G., McAdow M., Bagnoli F., Missiakas D.M., Schneewind O. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 2010, 28:6382.
88. Kim H.K., Cheng A.G., Kim H.-Y., Missiakas D.M., Schneewind O. Non-toxigenic protein A vaccine for methicillin-resistant Staphylococcusaureus infections. J. Exp. Med. 2010, 207:1863.
89. Kim H.K., Kim H.Y., Schneewind O., Missiakas D. Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J. 2011, 25:3605.
90. Kim H.K., Emolo C., DeDent A.C., Falugi F., Missiakas D.M., Schneewind O. Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice. Infect. Immun. 2012, 80:3460.
91. Kim H.K., Thammavongsa V., Schneewind O., Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr. Opin. Microbiol. 2012, 15:92.
92. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Craig A.S., Zell E.R., Fosheim G.E., McDougal L.K., Carey R.B., Fridkin S.K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763.
93. Klevens R.M., Edwards J.R., Gaynes R.P., System, N.N.I.S The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin. Infect. Dis. 2008, 47:927.
94. Koch R. The Ätiologie der Tuberkulose. Berl. Klin. Wochenschr. 1882, 19:221.
95. Kollef M.H., Morrow L.E., Niederman M.S., Leeper K.V., Anzueto A., Benz-Scott L., Rodino F.J. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006, 129:1210.
96. Kraft W.G., Johnson P.T., David B.C., Morgan D.R. Cutaneous infection in normal and immunocompromised mice. Infect. Immun. 1986, 52:707.
97. Kretschmer D., Gleske A.K., Rautenberg M., Wang R., Koberle M., Bohn E., Schoneberg T., Rabiet M.J., Boulay F., Klebanoff S.J., van Kessel K.A., van Strijp J.A., Otto M., Peschel A. Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus. Cell Host Microbe 2010, 7:463.
98. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., Noble L., Brown M.J., Zorman J.K., Wang X.M., Pancari G., Fan H., Isett K., Burgess B., Bryan J., Brownlow M., George H., Meinz M., Liddell M.E., Kelly R., Schultz L., Montgomery D., Onishi J., Losada M., Martin M., Ebert T., Tan C.Y., Schofield T.L., Nagy E., Meineke A., Joyce J.G., Kurtz M.B., Caulfield M.J., Jansen K.U., McClements W., Anderson A.S. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 2006, 74:2215.
99. Kuroda M., Ohta T., Uchiyama I., Baba T., Yuzawa H., Kobayashi I., Cui L., Oguchi A., Aoki K., Nagai Y., Lian J., Ito T., Kanamori M., Matsumaru H., Maruyama A., Murakami H., Hosoyama A., Mitsutani-Ui Y., Kobayashi N., Sawano T., Inoue R., Kaito C., Sekimizu K., Hirakawa H., Kuhara S., Goto S., Yabuzaki J., Kanehisa M., Yamashita A., Oshima K., Furuya K., Yoshino C., Shiba T., Hattori M., Ogasawara N., Hayashi H., Hiramatsu K. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 2001, 357:1225.
100. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., Greko C., So A.D., Bigdeli M., Tomson G., Woodhouse W., Ombaka E., Peralta A.Q., Qamar F.N., Mir F., Kariuki S., Bhutta Z.A., Coates A., Bergstrom R., Wright G.D., Brown E.D., Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 2013, 13:1057.
101. Lee J.C., Betley M.J., Hopkins C.A., Perez N.E., Pier G.B. Virulence studies, in mice, of transposon-induced mutants of Staphylococcus aureus differing in capsule size. J. Infect. Dis. 1987, 156:741.
102. Lessa F.C., Mu Y., Davies J., Murray M., Lillie M., Pearson A., Fridkin S.K. Comparison of incidence of bloodstream infection with methicillin-resistant Staphylococcus aureus between England and United States, 2006-2007. Clin. Infect. Dis. 2010, 51:925.
103. Lew D.P., Waldvogel F.A. Osteomyelitis. N. Engl. J. Med. 1997, 336:999.
104. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., Kaplan S.L., Karchmer A.W., Levine D.P., Murray B.E., M, J.R., Talan D.A., Chambers H.F. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 2011, 52:285.
105. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339:520.
106. Ma C.S., Chew G.Y., Simpson N., Priyadarshi A., Wong M., Grimbacher B., Fulcher D.A., Tangye S.G., Cook M.C. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 2008, 205:1551.
107. Malachowa N., Kobayashi S.D., Braughton K.R., DeLeo F.R. Mouse model of Staphylococcus aureus skin infection. Methods Mol. Biol. 2013, 1031:109.
108. Mathews W.C., Caperna J.C., Barber R.E., Torriani F.J., Miller L.G., May S., McCutchan J.A. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J. Acquir. Immune Defic. Syndr. 2005, 40:155.
109. Mazmanian S.K., Skaar E.P., Gaspar A.H., Humayun M., Gornicki P., Jelenska J., Joachmiak A., Missiakas D.M., Schneewind O. Passage of heme-iron across the envelope of Staphylococcus aureus. Science 2003, 299:906.
110. McAdow M., Kim H.K., Dedent A.C., Hendrickx A.P., Schneewind O., Missiakas D.M. Preventing Staphylococcus aureus Sepsis through the Inhibition of Its Agglutination in Blood. PLoS Pathog. 2011, 7:e1002307.
111. McAdow M., DeDent A.C., Emolo C., Cheng A.G., Kreiswirth B.N., Missiakas D.M., Schneewind O. Coagulases as determinants of protective immune responses against Staphylococcus aureus. Infect. Immun. 2012, 80:3389.
112. McCarthy A.J., Lindsay J.A. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 2010, 10:173.
113. McCormick J.K., Yarwood J.M., Schlievert P.M. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 2001, 55:77.
114. McDevitt D., Francois P., Vaudaux P., Foster T.J. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol. Microbiol. 1994, 11:237.
115. McDevitt D., Nanavaty T., House-Pompeo K., Bell E., Turner N., McIntire L., Foster T., Höök M. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur. J. Biochem. 1997, 247:416.
116. McKenney D., Pouliot K.L., Wang Y., Murthy V., Ulrich M., Doring G., Lee J.C., Goldmann D.A., Pier G.B. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999, 284:1523.
117. McRipley R.J., Whitney R.R. Characterization and quantitation of experimental surgical-wound infections used to evaluate topical antibacterial agents. Antimicrob. Agents Chemother. 1976, 10:38.
118. Mehlin C., Headley C.M., Klebanoff S.J. An inflammatory polypeptide complex from Staphylococcus epidermidis: isolation and characterization. J. Exp. Med. 1999, 189:907.
119. Menzies B.E., Kernodle D.S. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect. Immun. 1996, 64:1839.
120. Miller L.S., O'Connell R.M., Gutierrez M.A., Pietras E.M., Shahangian A., Gross C.E., Thirumala A., Cheung A.L., Cheng G., Modlin R.L. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006, 24:79.
121. Miller L.G., Quan C., Shay A., Mostafaie K., Bharadwa K., Tan N., Matayoshi K., Cronin J., Tan J., Tagudar G., Bayer A.S. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin. Infect. Dis. 2007, 44:483.
122. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., Kanno Y., Spalding C., Elloumi H.Z., Paulson M.L., Davis J., Hsu A., Asher A.I., O'Shea J., Holland S.M., Paul W.E., Douek D.C. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773.
123. Molne L., Verdrengh M., Tarkowski A. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect. Immun. 2000, 68:6162.
124. Nakamura Y., Oscherwitz J., Cease K.B., Chan S.M., Munoz-Planillo R., Hasegawa M., Villaruz A.E., Cheung G.Y., McGavin M.J., Travers J.B., Otto M., Inohara N., Nunez G. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature 2013, 503:397.
125. Napolitano L.M., Brunsvold M.E., Reddy R.C., Hyzy R.C. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia and ARDS: 1-year follow-up. Chest 2009, 136:1407.
126. Nilsson I.M., Hartford O., Foster T., Tarkowski A. Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Infect. Immun. 1999, 67:1045.
127. Novick R.P., Christie G.E., Penadés J.R. The phage-related chromosomal islands of Gram-positive bacteria. Nat. Rev. Microbiol. 2010, 8:541.
128. Ogston A. Report upon Micro-Organisms in Surgical Diseases. Br. Med. J. 1881, 1(369):b362.
129. Ogston A. Micrococcus Poisoning. J. Anat. Physiol. 1882, 17:24.
130. Otto M. A MRSA-terious enemy among us: end of the PVL controversy?. Nat. Med. 2011, 17:169.
131. Palmqvist N., Foster T.J., Tarkowski A., Josefsson E. Protein A is a virulence factor in Staphylococcus aureus arthritis and septic death. Microb. Pathog. 2002, 33:239.
132. Palmqvist N., Patti J.M., Tarkowski A., Josefsson E. Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. Microbes Infect. 2004, 6:188.
133. Panizzi P., Nahrendorf M., Figueiredo J.L., Panizzi J., Marinelli B., Iwamoto Y., Keliher E., Maddur A.A., Waterman P., Kroh H., Leuschner F., Aikawa E., Swirski F.K., Pittet M.J., Hackeng T.M., Fuentes-Prior P., Schneewind O., Bock P.E., Weissleder R. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat. Med. 2011, 17:1142.
134. Panton P.N., Valentine F.C.O. Staphylococcal toxin. Lancet 1932, 222:506.
135. Pishchany G., McCoy A.L., Torres V.J., Krause J.C., Crowe J.E., Fabry M.E., Skaar E.P. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe 2010, 8:544.
136. Placencia F.X., Kong L., Weisman L.E. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin. Pediatr. Res. 2009, 65:420.
137. Powers M.E., Kim H.K., Wang Y.-T., Bubeck-Wardenburg J. ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J. Infect. Dis. 2012, 206:352.
138. Price L.B., Stegger M., Hasman H., Aziz M., Larsen J., Andersen P.S., Pearson T., Waters A.E., Foster J.T., Schupp J., Gillece J., Driebe E., Liu C.M., Springer B., Zdovc I., Battisti A., Franco A., Zmudzki J., Schwarz S., Butaye P., Jouy E., Pomba C., Porrero M.C., Ruimy R., Smith T.C., Robinson D.A., Weese J.S., Arriola C.S., Yu F., Laurentk F., Keim P., Skov R., Aarestrup F.M. Staphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestock. mBio 2012, 3:e00305.
139. Proctor R.A. Challenges for a universal Staphylococcus aureus vaccine. Clin. Infect. Dis. 2012, 54:1179.
140. Proctor R.A. Challenges for a universal Staphylococcus aureus vaccine. Clin. Infect. Dis. 2012, 54:1179.
141. Ragle B.E., Bubeck-Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect. Immun. 2009, 77:2712.
142. Rauch S., Dedent A.G., Kim H.K., Bubeck Wardenburg J., Missiakas D.M., Schneewind O. Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection. Infect. Immun. 2012, 80:3721.
143. Reyes-Robles T., Alonzo F.r., Kozhaya L., Lacy D.B., Unutmaz D., Torres V.J. Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection. Cell Host Microbe 2013, 14:453.
144. Richter S.S., Diekema D.J., Heilmann K.P., Dohrn C.L., Crispell E.K., Riahi F., McDanel J.S., Satola S.W., Doern G.V. Activity of Vancomycin, Ceftaroline, and Mupirocin Against Staphylococcus aureus from a 2011 National Surveillance Study in the United States. Antimicrob. Agents Chemother. 2014, 58:750.
145. Rooijakkers S.H., Ruyken M., Roos A., Daha M.R., Presanis J.S., Sim R.B., van Wamel W.J., van Kessel K.P., van Strijp J.A. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 2005, 6:920.
146. Sader H.S., Flamm R.K., Jones R.N. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob. Agents Chemother. 2013, 57:3178.
147. Serruto D., Rappuoli R., Scarselli M., Gros P., van Strijp J.A. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat. Rev. Microbiol. 2010, 8:393.
148. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J., Yeoh H., Law D., Robbins J.B., Schneerson R., Muenz L., Fuller S., Johnson J., Fireman B., Alcorn H., Naso R. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 2002, 346:491.
149. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118.
150. Snowden J.N., Beaver M., Smeltzer M.S., Kielian T. Biofilm-infected intracerebroventricular shunts elicit inflammation within the central nervous system. Infect. Immun. 2012, 80:3206.
151. Soong G., Martin F.J., Chun J., Cohen T.S., Ahn D.S., Prince A. Staphylococcus aureus protein A mediates invasion across airway epithelial cells through activation of RhoA GTPase signaling and proteolytic activity. J. Biol. Chem. 2011, 286:35891.
152. Spaan A.N., Surewaard B.G.J., Nijland R., van Strijp J.A.G. Neutrophils versus Staphylococcus aureus: a biological tug of war. Annu. Rev. Microbiol. 2013, 67:629.
153. Spaan A.N., Henry T., van Rooijen W.J., Perret M., Badiou C., Aerts P.C., Kemmink J., de Haas C.J., van Kessel K.P., Vandenesch F., Lina G., van Strijp J.A. The staphylococcal toxin Panton-Valentine Leukocidin targets human C5a receptors. Cell Host Microbe 2013, 13:584.
154. Spoor L.E., McAdam P.R., Weinert L.A., Rambaut A., Hasman H., Aarestrup F.M., Kearns A.M., Larsen A.R., Skov R.L., Fitzgerald J.R. Livestock Origin for a Human Pandemic Clone of Community-Associated Methicillin-Resistant Staphylococcus aureus. mBio 2013, 13.
155. Sreeramoju P., Porbandarwalla N.S., Arango J., Latham K., Dent D.L., Stewart R.M., Patterson J.E. Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement. Am. J. Surg. 2011, 201:216.
156. Stearns-Kurosawa D.J., Osuchowski M.F., Valentine C., Kurosawa S., Remick D.G. The pathogenesis of sepsis. Annu. Rev. Pathol. Mech. Dis. 2010, 6:19.
157. Stevens D.H., Herr D., Campiris H., Hunt J.L., Batts D.H., Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 2002, 34:1481.
158. Stockinger B., Veldhoen M. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 2007, 19:281.
159. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16942.
160. Sullam P.M., Bayer A.S., Foss W.M., Cheung A.L. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect. Immun. 1996, 64:4915.
161. Surewaard B.G., Nijland R., Spaan A.N., Kruijtzer J.A., de Haas C.J., van Strijp J.A. Inactivation of staphylococcal phenol soluble modulins by serum lipoprotein particles. PLoS Pathog. 2012, 8:e1002606.
162. Sutter D.E., Summers A.M., Keys C.E., Taylor K.L., Frasch C.E., Braun L.E., Fattom A.I., Bash M.C. Capsular serotype of Staphylococcus aureus in the era of community-acquired MRSA. FEMS Immunol. Med. Microbiol. 2011, 63:16.
163. Szabo E.K., MacCallum D.M. The contribution of mouse models to our understanding of systemic candidiasis. FEMS Microbiol. Lett. 2011, 320:1.
164. Talan D.A., Krishnadasan A., Gorwitz R.J., Fosheim G.E., Limbago B., Albrecht V., Moran G.J. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin. Infect. Dis. 2011, 53:144.
165. Tarkowski A., Collins L.V., Gjertsson I., Hultgren O.H., Jonsson I.M., Sakiniene E., Verdrengh M. Model systems: modeling human staphylococcal arthritis and sepsis in the mouse. Trends Microbiol. 2001, 9:321.
166. Thammavongsa V., Kern J.W., Missiakas D.M., Schneewind O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J. Exp. Med. 2009, 206:2417.
167. Thammavongsa V., Schneewind O., Missiakas D.M. Enzymatic properties of Staphylococcus aureus adenosine synthase (AdsA). BMC Biochem. 2011, 12:56.
168. Thammavongsa V., Missiakas D.M., Schneewind O. Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science 2013, 342:863.
169. Thiene G., Basso C. Pathology and pathogenesis of infective endocarditis in native heart valves. Cardiovasc. Pathol. 2006, 15:256.
170. Tkaczyk C., Hua L., Varkey R., Shi Y., Dettinger L., Woods R., Barnes A., MacGill R.S., Wilson S., Chowdhury P., Stover C.K., Sellman B.R. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin. Vaccine Immunol. 2012, 19:377.
171. Torres V.J., Pishchany G., Humayun M., Schneewind O., Skaar E.P. Staphylococcus aureus IsdB is a hemoglobin receptor required for heme-iron utilization. J. Bacteriol. 2006, 188:8421.
172. Troidle L., Finkelstein F. Treatment and outcome of CPD-associated peritonitis. Ann. Clin. Microbiol. Antimicrob. 2006, 5:6.
173. Viana D., Blanco J., Tormo-Más M.A., Selva L., Guinane C.M., Baselga R., Corpa J.M., Lasa I., Novick R.P., Fitzgerald J.R., Penadés J.R. Adaptation of Staphylococcus aureus to ruminant and equine hosts involves SaPI-carried variants of von Willebrand factor-binding protein. Mol. Microbiol. 2010, 77:1583.
174. von Eiff C., Becker K., Machka K., Stammer H., Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 2001, 344:11.
175. von Köckritz-Blickwede M., Rohde M., Oehmcke S., Miller L.S., Cheung A.L., Herwald H., Foster S., Medina E. Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am. J. Pathol. 2008, 173:1657.
176. Voyich J.M., Otto M., Mathema B., Braughton K.R., Whitney A.R., Welty D., Long R.D., Dorward D.W., Gardner D.J., Lina G., Kreiswirth B.N., DeLeo F.R. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J. Infect. Dis. 2006, 194:1761.
177. Wade C.M., Daly M.J. Genetic variation in laboratory mice. Nat. Genet. 2005, 37:1175.
178. Wang R., Braughton K.R., Kretschmer D., Bach T.H., Queck S.Y., Li M., Kennedy A.D., Dorward D.W., Klebanoff S.J., Peschel A., DeLeo F.R., Otto M. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 2007, 13:1510.
179. Weichert S., Sharland M., Clarke N.M., Faust S.N. Acute haematogenous osteomyelitis in children: is there any evidence for how long we should treat?. Curr. Opin. Infect. Dis. 2008, 21:258.
180. Weigel L.M., Clewell D.B., Gill S.R., Clark N.C., McDougal L.K., Flannagan S.E., Kolonay J.F., Shetty J., Killgore G.E., Tenover F.C. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003, 302:1569.
181. Wiles S., Hanage W.P., Frankel G., Robertson B. Modelling infectious disease - time to think outside the box? Nature reviews. Microbiology 2006, 4:307.
182. Wilke G.A., Bubeck Wardenburg J. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13473.